Organisation paid for research Program year 2025 Source: CMS Open Payments

Troy Internal Medicine Research

Neither a doctor nor a teaching hospital

Research payments

$1,090,032

768 payments

Through program year 2025, Troy Internal Medicine Research is reported as receiving $1,090,032 in research payments, across 768 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $271,489 4
2024 Research $200,169 7
2023 Research $248,543 286
2022 Research $293,944 385
2021 Research $37,549 3
2020 Research $38,337 83

Breakdown

Who paid Research payments · program years 2020–2025
  1. Novartis Pharmaceuticals Corporation $966,212 19 payments
  2. Novo Nordisk AS $123,293 748 payments
  3. Eli Lilly and Company $526 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease $619,415 7 payments
  2. An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $215,599 5 payments
  3. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $127,645 5 payments
  4. Nn9535-4820 $83,250 452 payments
  5. Nn9535-4984 $36,686 214 payments
  6. A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure $3,554 2 payments
  7. Nn1436-4477 $3,357 82 payments
  8. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $526 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record